. . 1,3, . . 1, . . 2, . .

18.02.11. 27.03.11.
,
, . ,
, . ,
.
: , .

. ,
[1, 2]. [3, 4].
: ,
,
,
, .
, . ,
,
.
, , ,

( ),
, 1

. . . , 119571
, - , . 86.

. . . , 119991 , . , . 32

E-mail alex.kaplun@mail.ru

, [5]. ,


(100 600 );
, [6].

- -?
. ,
,
, , .
4, (, ) [7, 8] 0,2 1
100 . ,
. ,
(10 ), , . ,
,
,
100 .
. ,
,
:
4

28

: ,
1 100 .

. 2011. . 3. 2. . 28 40

60 70 (~5 ).
<40 .

200 600 .
?
() 60
, .
() 40
, , .
() 100 600
(, ).

< 60 , .
, 200 , , , 20- [9].
, 600 [10].
, , :
,

;
,
, ;
, .
.

. . . , 2006 . [11],
.
? : (, ,
. .);
. .
. , , .
[12],
, :
, , , ,
, , , , , , .
(. 1). ,
, .

, -

. 1. . [12]
-

++

++

40 1000

50 900

40 900

300 1500

40 1000

++

++

++

++

++

++

++

++

++

++

++

++

++

++

++

++

++

. 2011. . 3. 2. . 28 40

29

. . , . . , . . , . .

. 3. - .

. 1.
: 1 ; 2 ; 3
3--.

. 2. ( )
(
).

.
, ,

(
)
, ,
()
[13]. : (56 68 %), (25 30 %)

30

3-- (7 9 %) (. 1).
(. 2).
,
, [11]
[14]. , ,
, .
,
: , , ,
(,
) [11].
- ; ,
- ,
.
,
- - . ,
. .
, (. 3).
, ( )
, , ,
, ,
, .

- -

. 2011. . 3. 2. . 28 40

. 4. , : 3; 5; 7; 9. 200 .

, , -
- (50 ). , -,
.

,
(, [15, 16, 17]),
, , ,

. 2011. . 3. 2. . 28 40

31

. . , . . , . . , . .

. 5. , / , .

. 6. (1 110 ).

,
9 %. [18]

0,5 6,2 %, .
, , .
,
8,69 9,07. ,
50 % ( )
9 1 % 7 .

, .
, 7

: , 3, 5, 7,

.
(. 4) , 9
. , , -

32

,

(. 4, , 4, ).
, , ,

. : ,
. , . , ,
, ,
(. 5). ( ).
, ;

; . .
,
, , .
, ,

. , ,
, , . , ,
,
,
,
(. 6).
, ,
, . .

.
[19].
(. 7) ,

.

. 2011. . 3. 2. . 28 40

. 7.
, (a),
( ).

,
.
, . (. 7, )
[20].

( , : 9,01, 10,98 11,97),

. ,
( ,
, ,
-

, ) (. 8)
5 20 %. . ,
,
. 9.
5 %
,
, .


, - . ,
(, ), - 50 +35 .

, , . ,
(. 10).
,
, - , -, 20 %
, .

,
, , .

.

3-.
. 11
: ,
. , .

[21, 22].

(50 < 5 /).
,
(. 12).

. 2011. . 3. 2. . 28 40

33

. . , . . , . . , . .

ImageMaster 2D Platinum software

, .
:
, (-IV,
J, ), , ,
, .

ImageJ (National Institutes of
Health, ) Phoretix 2D v. 6.01
software (Phoretix Intl., Durham,
NC)
-, , (. 2).
(Ig
G, , )

. (, ) .
, -IV
. -I -IV -
, , ,
. 8. , , : 1 ; 2 -
; 3 ; 4 ; 5 - ; 6 ; 7 ; 8 .
(. .
).
, ,
, ;
. . ,
,

. .
: ( in vivo
) [23 29].
[30],
[31] ; -1 (. 13).
1 - (2D-PAGE)
.., - [32].
, PYNNY.
-

34

. 2011. . 3. 2. . 28 40

[30]. , ,

100 /
(114 6 /)

. 9. , ,
.

2 ,
(189 11 /) 3 .

. 10. (1,6 /)
(13,5, 18,0, 23,1,
27,0 /).

. 11. 30 , 3-; ,
; , , .
1 .

. 2011. . 3. 2. . 28 40

35

. . , . . , . . , . .

1 -
(. 14, 15).
, , - 2. , (
-)
. 12. , , , .

,
[33].
. ,


.
(3-) .

, ,
%

Ig (a-)

6.8

13.4

16.8

(a-)

7.5

(g-)

4.9

IgG ( g-)

6.9

(b-)

3.5

(a + b-)

8.8

Ig ( )

16.7

-IV

4.8

ApoJ

6.2

ApoE

3.6

. 13. - (2D-PAGE) , , , .

36

. 2011. . 3. 2. . 28 40

. 14. 1 ; - (3-); .

, .
(. 14) , .
(. 15)
, .

:
(.. 261 [34], . . 215 216 [35]),
, -

? , ,
.
, (. 16).
,
/ 0,77.

400 (. 17).
4

, . 16 -

. 15. . . 1000- .

. 2011. . 3. 2. . 28 40

37

. . , . . , . . , . .

. 16.
450 /.

,
. ,
.


[36].
,
[37], , .
,
- , . -

, .

, , , ,


,
.
,
, .
.

[38, 39].
,
.

38

. 17.
0,77 400 ( )
4 ( )
3 4 ,
16
, ( ).

[40] , .


.
-

. 2011. . 3. 2. . 28 40

3.

++

++

20 200

++

++

. , ,
( ), 70 300 .
,

,
.
,
, IC50 .
,
, , ,
(
).

. 3
.
, ,
,
, .

, : . . , . . , . . , . . ; ...
. . ()

; . () .

2.1.1/9349 (2009 2011 .)
2011 .

1. Jong D., Borm J. / Int. J. Nanomed. 2008. V. 3(2).
P. 133 149.
2. Packhaeuser C., Schnieders J., Oster C., Kissel T. /
Eur. J. Pharm. Biopharm. 2004. V. 58. P. 445 455.
3. . ., , . ., . . / . .
1999. . 45. . 1. . 3 12.
4. . ., . ., . .,
. ., . . / . . 2008. . 3. 11 12. . 52 66.
5. Love W., Amos N., Kellaway I., Williams B. / Ann.
Rheum. Dis. 1990. V. 49(8). P. 611 614.
6. Hobbs S.,
Monsky W.,
Yuan F.,
Roberts W.,
Griffith L., Torchilin V., Jain R. / Proc. Natl. Acad.
Sci. USA. 1998. V. 95. P. 4607 4612.
7. http://www.rusnano.com/Rubric.aspx?RubricId=260.
8. http://www.nanotec.org.uk/report/Nano_%20report_
%202004_%20fin.pdf.
9. Amrite A., Edelhauser H., Singh S., Kompella U. /
Mol. Vision. 2008. V. 14. P. 150 160.
10. Hoffman R. / J. Drug Target. 1998. V. 5(2) P. 67 74.
11. Torchilin V. (ed.) / Nanoparticulates as Drug Carriers. Imperial College Press, 2006. P. 724.
12. Kayser O., Kiderlen A. / Exp. Opin. Investig. Drugs.
2003. V. 12. P. 1 11.
13. . ., . ., . .,
. ., . ., . .,
. ., . . / .
2008. 6. . 51 59.
14. Mller R., Mader K., Gohla S. / Eur. J. Pharm.
Biopharm. 2000. V. 50. P. 161 177.
15. Kovac-Besovic E., Duric K., Kalodera Z., Sofic E. /
Bosn. J. Basic. Med. Sci. 2009 V. 9(1). P. 31 38.
16. Kuznetsov B., Efremov A., Levdanskii V., Polezhaeva N., Shilkina T., Kronova I. / Biores. Technol.
1996. V. 58. P. 181 188.
17. . ., . ., . .,
. ., . ., . .,
. . / . . . 2008. 1.
. 45 49.
18. Krasutsky P. A. / Nat. Prod. Rep. 2006. V. 23, P. 919 942.
19. . . / . , 1956.
20. Zhang H., Zhao H., Wang J., Chen J., Lu Y., Yun J. /
Small. 2009. V. 5(16). P. 1846 1849.
21. . ., . ., . . /
, RU 2252775,
2005.
22. . ., . ., . ., . ., . ., . .,

. 2011. . 3. 2. . 28 40

39

. . , . . , . . , . .

23.

24.
25.
26.
27.
28.
29.
30.

. ., . . / , RU 2355423, 2009.
Luck M., Paulke B., Schrder W., Blunk T., Mller R.
/ Analysis of Plasma Protein Adsorption On Polymeric Nanoparticles with Different Surface Characteristics. John Wiley & Sons, Inc., 1998.
P. 478 485.
Gppert T., Mller R. / Int. J. Pharm. 2005. V. 302.
P. 172 186.
Torsten M., Gppert T., Mller R. / Eur. J. Pharm.
Biopharm. 2005. V. 60. P. 361 372.
Schmidt S., Mller R. / Int. J. Pharm. 2003. V. 254.
P. 3 5.
Blunk T., Hochstrasser D., Sanchez J., Mller B.,
Mller R. / Electrophoresis. 1993. V. 14. P. 1382 1387.
Gppert T., Mller R. / J. Drug Target. 2005.
V. 13(3). P. 179 187.
Gessner A., Paulke B., Mller R. / Electrophoresis.
2000. V. 21. P. 2438 2442.
. ., . ., . .,
. . / ,
RU 2300389, 2007.

31. . ., . ., . .,
. ., . . / , RU 2324492, 2008.
32. . ., . ., . .,
. . / , RU
2353379, 2009.
33. http://clinicaltrials.gov/ct2/show/NCT00346502.
34. Jaaskelainen P. / Paperi ja Puu. 1981. V. 63(10).
P. 599 603.
35. Pradhan B. P., Hassan A., Ray T. / Tetrahedron.
1985. V. 41(12). P. 2513 2516.
36. Wegener M., Fevre M., Paschedag A., Kraume M. /
Int. J. Heat Mass Transfer. 2009. V. 52(11 12).
P. 2543 2551.
37. Wegener M., Paschedag A., Kraume M. / Int. J. Heat
Mass Transfer. 2009. V. 52. P. 2673 2677.
38. Medina C., Santos-Martinez M., Radomski A.,
Corrigan O., Radomski M. / Br. J. Pharmacol. 2007.
V. 150. P. 552 558.
39. Yang H., Liu C., Yang D., Zhang H., Xi Z. / J. Appl.
Toxicol. 2009. V. 29. P. 69 78.
40. McGovern S., Caselli E., Grigorieff N., Shoichet B. /
J. Med. Chem. 2002. V. 45(8). P. 1712 1722.

SPHERICAL AMORPHOUS NANOPARTICLES

FROM BIRCH BARK TRITERPENOIDS A NOVEL TYPE
OF SUBMICRONIC VEHICLE FOR DRUG DELIVERY
A. P. Kaplun,1,3 D. A. Bezrukov,1 V. I. Popenko,2 V. I. Shvets1
1
2
3

M. V. Lomonosov Moscow State Academy of Fine Chemical Technology, 119571 Moscow, Vernadskogo av., 86.
Engelhardt Institute of Molecular Biology RAS, 119991 Moscow, Vavilov str., 32.
alex.kaplun@mail.ru

In the review the experimental data, concerning spherical amorphous nanoparticles, obtained
from birch bark triterpenoids are considered. The questions mentioning the mechanism of formation of these nanoparticles, their properties are discussed. It is shown that they can serve as a vehicle for hydrophobic drugs as immunological adjuvants.
Keywords: birch bark triterpenoids, spherical amorphous nanoparticles.

40

. 2011. . 3. 2. . 28 40